CD274 and neoplasm: Interestingly, this stands in sharp contrast to the oncology setting, where systemic PD-1/PD-L1 blockade with immune checkpoint inhibitors (e.g., nivolumab and pembrolizumab) enhances anti-tumour immunity but frequently induces immune-related adverse events (irAEs), such as inflammatory arthritis [47].